6α-Methyl-17α-HYDROXYPROGESTERONE 17-ACYLATES; A NEW CLASS OF POTENT PROGESTINS<sup>1</sup>

Babcock, John C.; Gutsell, Erwin S.; Herr, Milton E.; Hogg, John A.; Stucki, Jacob C.; Barnes, Lester E.; Dulin, W. E.

doi:10.1021/ja01544a079

Cited by 89 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). These drugs have been known since the 1960s (46)(47)(48), and the first clinical trial in breast cancer, using a low dose, showed a response rate of 17-18% (49). A breakthrough came when an Italian group published results of using MPA i.m.…”

Section: Some Newer Treatment Modalitiesmentioning

confidence: 99%

Progestins in Breast Cancer Treatment: A Reveiw

Lundgren

1992

Acta Oncologica

View full text Add to dashboard Cite

The two most widely used synthetic progestins in breast cancer treatment, medroxyprogesterone acetate (MPA) and megestrol acetate (MA), are reviewed with regard to pharmacological, endocrinological and clinical aspects. In high oral doses as second- or first-line endocrine therapy in advanced breast cancer, they give a similar response rate as tamoxifen (TAM) and aminoglutethimide (AG). The mechanism of action is probably complex. Considerable changes in serum levels of different hormones are induced by progestin treatment. The decrease of serum estrone sulfate (E1S) may be part of the therapeutic mechanism. Some studies suggest that the two drugs, MPA and MA, have a different mode of action, and possibly a low cross resistance. Randomized studies using the two progestins with a cross-over design may answer these questions. Further studies on the influence of progestin on different receptors and growth factors are warranted. To determine the most effective clinical dose of the two progestins, studies with increasing therapeutic doses are needed.

show abstract

Section: Some Newer Treatment Modalitiesmentioning

confidence: 99%

Progestins in Breast Cancer Treatment: A Reveiw

Lundgren

1992

Acta Oncologica

View full text Add to dashboard Cite

show abstract

“…NET-EN was the first injectable progestin used as a contraceptive under the trade name Noristerat. At the same time scientists in the USA developed depomedroxyprogesterone acetate (DMPA) under the trade name Depo-Provera [6]. Trials for both were started in 1965 and the methods appeared promising, at a time when the estrogen component in the combined oral contraceptive pill was receiving considerable adverse publicity resulting from reports of major side-effects.…”

Section: Lnjectablesmentioning

confidence: 99%

Long-acting progestins — an update

1989

View full text Add to dashboard Cite

“…The progestational potencies of these compounds vary widely( 3: 4,5,8,9). the relative androgenic potency of the series of compounds must be considered in relation to the potency of therapeutic activity.…”

Section: (7)mentioning

confidence: 99%